This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vical's CEO Presents At Bank Of America Merrill Lynch Health Care Conference Call (Transcript)

So without getting into how the mechanism works I think the key thing is it’s a unique mechanism and the unique mechanism is such a way that you treat the tumour to teach the immune system to recognize what’s wrong with the cancer and UE use the lesion while you inject Allovectin as a classroom and that classroom is really teaching the immune system. Some immune systems learn very quickly, some immune systems take about 8, 10, 12 months before they learn. And that learning of the immune system is breaking of tolerance or teaching the immune system to recognize what’s wrong with that tumor getting it to recognize the markers that the cancer cell presents on the surface telling the immune system kill me, okay.

The most important thing is the newly approved drug therapy, immunotherapy Yervoy which is known as CTLA mAb. In animal studies we’ve shown that we’ve synergy with our therapy, a combination of Allovectin and CTLA mAb actually did better than CTLA mAb alone, so if this translates into human our drug that immunotherapy should have synergistic affects. So Vijay what’s the data.

Well Phase 2 trial which we did on 127 patients it’s a single-arm open-label study pretty large for a single-arm open-label study. 50% of the patients where stage 3, 50 % of those patients were stage 4, the key thing is the patients did not have brain mets and liver mets why? Because patients with brain mets and liver mets die very quickly and immunotherapy in order for the patient to benefit, they need to live long enough. What did we accomplish in that study we demonstrated first of all the drug was safe and efficacious, that’s key.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs